Back to Search
THOMAS GAJEWSKI, PHARMD
PHARMD
Pharmacist
NPI: 1891962320Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
5302033986(MI)
Research & Publications (20)
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
PMID 19597729·Cancer Chemother Pharmacol·2010
3-trial
Costimulatory and coinhibitory receptors in anti-tumor immunity.
PMID 19426219·Immunol Rev·2009
6-review
Emerging strategies in regulatory T-cell immunotherapies.
PMID 19288606·Clin Adv Hematol Oncol·2009
6-review
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
PMID 18942640·Prostate·2009
8-other
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.
PMID 19454668·J Immunol·2009
7-preclinical
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
PMID 19139427·J Clin Oncol·2009
3-trial
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
PMID 19052742·Cancer Immunol Immunother·2009
5-case
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
PMID 19417208·Blood·2009
7-preclinical
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
PMID 19658092·Eur J Immunol·2009
7-preclinical
Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway.
PMID 19414753·J Immunol·2009
7-preclinical
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
PMID 19293190·Cancer Res·2009
8-other
Melanoma presenting as circulating tumor cells associated with failed angiogenesis.
PMID 18626315·Melanoma Res·2008
5-case
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells.
PMID 18792400·Eur J Immunol·2008
7-preclinical
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells.
PMID 18177887·J Immunol Methods·2008
7-preclinical
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
PMID 18483384·Clin Cancer Res·2008
7-preclinical
Diagnosis and treatment of mycoplasma-contaminated cell cultures.
PMID 18770641·Curr Protoc Cytom·2008
8-other
The expanding universe of regulatory T cell subsets in cancer.
PMID 17723212·Immunity·2007
7-preclinical
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
PMID 17875753·Clin Cancer Res·2007
6-review
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.
PMID 17897636·Cell Immunol·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 229 N 3RD ST
ROGERS CITY, MI 49779 - Phone
- (989) 734-4701
Quick Facts
- NPI
- 1891962320
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile